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Background. Despite improvements in dialysis care, anemia
remains a problem in pediatric hemodialysis patients.
Methods. To assess possible explanations for the anemia, clin-
ical data were obtained from the Centers for Medicare and
Medicaid Services on all hemodialysis patients ages 12 to 18
years between October and December 2000. Complete data
were available for 435 of the 516 patients (84%).
Results. A total of 160 (37%) patients had a mean hemoglo-
bin of11 g/dL (anemic). The mean (SD) age for these patients
was 15.5  1.8 years compared to 15.9  1.5 years for the
target hemoglobin patients (P  0.05). Mean time on chronic
dialysis was similar for both the anemic and target hemoglobin
patients (100 g/dL) (3 years) but patients on dialysis 6
months were more likely to be anemic (67%). While nearly
all patients were treated with erythropoietin, anemic patients
received greater weekly erythropoietin doses (intravenous,
anemia 374  232 units/kg/week vs. target hemoglobin 246 
196 units/kg/week, P  0.001; and subcutaneous, 304  238
units/kg/week vs. 167  99 units/kg/week, P  0.05). A total
of 59% of anemic patients had a mean transferrin saturation
(TSAT) 20% compared to 71% of patients with a target
hemoglobin (P 0.01). A mean serum ferritin100 ng/mL was
present in  two thirds of the anemic and target hemoglobin
patients. Approximately 60% of all children were treated with
intravenous iron. The mean Kt/V values were lower for anemic
patients (1.46  0.4 vs. 1.53  0.3, P  0.05). Anemic patients
were less likely to have a normal serum albumin (29% anemic
vs. 52% target hemoglobin patients, P  0.001).
Conclusion. In the final multivariable regression model,
dialyzing6 months, a low albumin, and a mean TSAT20%
remained significant predictors of anemia in children.
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The Centers for Medicare and Medicaid Services (CMS)
launched the End-Stage Renal Disease (ESRD) Clinical
Performance Measures (CPM) Project, formally the ESRD
Core Indicators Project [1], to assess the care provided to
patients maintained on chronic dialysis and to stimulate
improvement in that care [2]. Prior to 2000, only patients
18 years and older were reported in the published analy-
ses. Beginning in that year, however, pediatric hemodial-
ysis patients, ages 12 to 18 years, were included in the
ESRD CPM Project data collection [3]. The ESRD CPM
Project provided the first comprehensive glimpse into
pediatric ESRD outcomes based on a nationally validated
data set. The generation of such data on children with
ESRD should assist in the establishment of pediatric
specific guidelines. Evolving guidelines for clinical care
of pediatric patients may well differ from those already
established for adults.
Despite the advances in dialysis care and the use of
erythropoietin, anemia continues to be a clinical problem
seen in patients with ESRD. Approximately 25% of
adult patient maintained on chronic hemodialysis have
anemia defined by the National Kidney Foundation Dial-
ysis Outcome Quality Initiative (K/DOQI) as a hemoglo-
bin value less than 11 g/dL [4]. There appears to be an
increase in morbidity and mortality, especially cardiovas-
cular morbidity, in dialysis patients with anemia being a
significant risk factor [5–9]. Upward of 75% of children
with anemia maintained on chronic hemodialysis exhibit
signs of left ventricular hypertrophy, a harbinger of car-
diovascular morbidity in adulthood [10]. The prevalence
of anemia and its associated morbidity in children main-
tained on chronic dialysis has yet to be fully determined.
In this report, data on the prevalence of anemia, its
management, and its likely contributing factors were col-
lected on all children ages 12 to 18 years of age who
were in-center hemodialysis patients treated between
October and December 2000.
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METHODS
All children ages 12 to 18 years maintained on
chronic in-center hemodialysis identified by the 18 ESRD
Networks as alive on December 31, 2000 were incorpo-
rated into the data set. Staff at individual dialysis units
recorded patient-specific parameters, including patient
demographics, years on dialysis, access type, dialysis clear-
ance, management of anemia, and serum albumin onto
data collection forms. The clinical information was col-
lected from October to December 2000. Completed forms
on each patient were returned to the appropriate net-
work office and then entered into a computerized data-
base (Visual FoxPro, Microsoft Corporation, Redmond,
WA, USA). Once entered and aggregated, the data were
sent to CMS for analysis.
To be part of the final analysis, the patient form had
to have the required descriptive information and at least
one hemoglobin, one paired pre- and postdialysis blood
urea nitrogen (BUN), and one serum albumin over the
October to December study period. Kt/V values were
calculated using the Daugirdas II formula [11]. All fac-
tors considered conceptually important and significantly
associated with anemia were entered into the multivari-
able analysis model. These factors included gender, race,
(only black and white due to small numbers in other
racial categories), Hispanic ethnicity, age, cause of ESRD,
duration of dialysis (6 months vs. 6 months or longer),
mean single-pool Kt/V, access type, postdialysis body
weight, mean serum ferritin concentration, mean trans-
ferrin saturation (TSAT) 20% vs. 20%, prescribed
dose of erythropoietin, and mean serum albumin 3.5/
3.2 g/dL vs.3.5/3.2 g/dL bromcresol green (BCG)/brom-
cresol purple (BCP) laboratory methods. Both forward
and backward elimination techniques utilizing the likeli-
hood ratio statistic were employed. Unless otherwise indi-
cated, data are expressed as mean  the standard devia-
tion with P values of less than 0.05 considered significant.
All statistic analyses were conducted using Epi Info,
version 6.04 [12] and SPSS for Windows, version 10.0 [13].
RESULTS
A complete data collection form was available for 435
of the 516 patients (84%). Of the patients, 37% (160 of
435) were found to have a mean hemoglobin of 11
g/dL (anemia) in the data collection period. Gender, race,
ethnicity, and cause of ESRD did not correlate with the
anemia (Table 1). The mean ( SD) age for the children
with anemia was slightly younger than that of the patients
with a target hemoglobin (11 g/dL) (15.5  1.8 years
vs. 15.9  1.5 years, P  0.05). Overall, the number of
years maintained on chronic dialysis was similar for both
the anemic and target hemoglobin patients. However,
anemia was more common among children who were on
dialysis less than 6 months (48 of 72 patients) (67%)
Table 1. Patient characteristics
Mean hemoglobin Mean hemoglobin
11 g/dL 11 g/dL
Characteristic Number (%) Number (%)
Total number of patients 275 (100) 160 (100)
Male 153 (56) 77 (48)
White 127 (46) 72 (45)
Black 114 (41) 71 (44)
Hispanic 68 (25) 33 (21)
Age (meanSD/median)
yearsa 15.91.5/16.2 15.51.8/15.8
Causes of ESRD
Congential/urologic 65 (24) 40 (25)
Other causes combined 114 (41) 70 (44)
Duration of dialysis (mean
SD/median) years 3.13.5/1.8 2.93.7/1.3
Post dialysis body weight
(mean  SD/median) kg 55.518.6/50.5 56.021.7/52.0
aP  0.05
compared to children dialyzing 6 months or longer (110
of the remaining 359 patients) (31%) (P  0.001).
Nearly all children were treated with erythropoietin
with no differences between the routes of administration
(Table 2). Children with anemia received higher weekly
erythropoietin doses (intravenous, anemia 374  232
units/kg/week vs. target hemoglobin 246  196 units/kg/
week, P  0.001; and subcutaneous, anemia 304  238
units/kg/week vs. target hemoglobin 167  99 units/kg/
week, P  0.05). A total of 59% of anemic children had
a mean TSAT 20% compared to 71% of the patients
with target hemoglobin (P  0.01). However, patients
having a mean serum ferritin concentration100 ng/mL
had no effect on the presence of anemia. Sixteen percent
of anemic children and 5% of children with target hemo-
globin were relatively iron deficient (defined as a mean
TSAT 20% and a mean serum ferritin concentration
of 100ng/mL; P  0.001). Approximately 60% of the
children were treated with intravenous iron but the dose
given was not available for analysis. Treatment with oral
iron was not different in the anemic versus children with
a target hemoglobin but again there was no information
on dosages prescribed and patient compliance.
The calculated single-pool Kt/V of 1.2 or greater de-
fined dialysis adequacy. The mean Kt/V values were some-
what lower for anemic children (1.46  0.4 vs. 1.53 
0.3, P 0.05). Consistent with the lower Kt/V, catheters
were more commonly used as access in anemic children
(anemia 61% vs. target hemoglobin 36%, P  0.001).
Moreover, mean dialysis blood pump flows were lower
for patients with anemia (276  80 mL/min vs. 320 
79 mL/min, P  0.001). Median Kt/V values were not
different in anemic vs. target hemoglobin children with
a fistula or graft (anemia Kt/V 1.52  0.35 vs. target
hemoglobin 1.58  0.31; P  0.279). Within the subset
of children dialyzed using catheters, anemic patients had
similar clearances (anemia Kt/V 1.42  0.35 vs. target
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Table 2. Clinical indicators of care
Mean hemoglobin Mean hemoglobin
11 g/dL 11 g/dL
Characteristic Number (%) Number (%)
Total number of patients 275 (100) 160 (100)
Anemia management
Number of patients prescribed erythropoietin
Intravenous 250 (92) 138 (90)a
Subcutaneous 21 (8) 18 (12)
Weekly erythropoietin dose (meanSD/median) units/kg/week
Intravenousb 246196/192 374232/320
Subcutaneousc 16799/138 304238/216
Mean transferrin saturation 20%c 196 (71) 94 (59)
Mean serum ferritin concentration 100 ng/mL 194 (71) 103 (64)
Relative iron deficiencyb 14 (5) 25 (16)
Number of patients prescribed intravenous iron 174 (63) 95 (59)
Clearance data
Kt/V (meanSD/median)d 1.530.3/1.51 1.460.4/1.45
Blood pump flow (meanSD/median)b mL/min 32079/317 27680/287
Vascular access
Arteriovenous fistulab 106 (39) 28 (18)
Arteriovenous graft 71 (26) 35 (22)
Catheterb 98 (36) 97 (61)
aA few patients received both intravenous and subcutaneous erythropoietin; bP  0.001; cP  0.01; dP  0.05
Fig. 1. Percent of children maintained on chronic hemodialysis with a
normal albumin and anemia.
hemoglobin 1.44  0.28) and pump flows (anemia 263 
71 mL/min vs. target hemoglobin 282  69 mL/min)
compared to patients with a target hemoglobin. Finally,
children with anemia were less likely to have a normal
serum albumin characterized as a value  4.0/3.7 g/dL
BCG/BCP methods (Fig. 1).
The association between lower serum albumin and
anemia was still present in the subset of children dialyzed
exclusively with catheter access when clearance and pump
flow were no longer active variables (albumin 3.56 
Table 3. Final model predicting anemia (hemoglobin 11 g/dL)
Odds ratio
Predictor (95% confidence intervals) P value
Duration of dialysis
6 months 3.5 (1.9, 6.5) 0.001
Mean serum albumina
3.5/3.2 g/dL 3.2 (1.8, 5.8) 0.001
Mean transferrin
saturation 20% 1.9 (1.2, 3.2) 0.01
a Bromcresol green (BCG)/bromcresol purple (BCP) laboratory methods
0.53 g/dL for anemic patients vs. 3.89  0.46 g/dL for
patients with a target hemoglobin by the BCG method;
P  0.001). After controlling for demographic and clini-
cal parameters, final predictors of anemia were being
new to dialysis, a lower serum albumin, and probable
iron deficiency as summarized in Table 3.
DISCUSSION
Despite the extensive use of erythropoietin and pre-
scribed iron supplements, over one third of children ages
12 to 18 maintained on chronic hemodialysis have a
mean hemoglobin of less than 11 g/dL. In the initial
analysis, lower solute clearances and lower serum albu-
min were factors that correlate with anemia in these
patients. Patients new to dialysis (treated less than 6
months) were more anemic. The degree of anemia prior
to the onset of dialysis may account for this finding but
this could not be statistically assessed from the CPM
data set. The years on hemodialysis, however, did not
seem to be a significant factor.
Children with anemia were more likely to be dialyzed
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using catheter access, had lower pump speeds, and had
somewhat lower Kt/V values. Nonetheless, the mean
dialysis adequacy (Kt/V 1.46  0.4) for the anemic chil-
dren dialyzed with catheters exceeded the K/DOQI
clearance guidelines for adult hemodialysis patients
[14, 15] (Kt/V1.2 per treatment). It came as no surprise
then when we observed that, after adjusting for gender,
race, and other variables in the multivariate analysis,
dialysis clearance no longer appeared to be an important
factor accounting for the anemia in these patients. The
questions still to be asked are: is there a point beyond
which increasing Kt/V brings little further benefit and
could the anemia really stem from variables other than
adequacy?
It is likely that catheter use is directly related to lower
dialysis pump flows and clearances. At present, there does
not appear to be a link between catheter use per se and
anemia independent of clearance as a variable. While
fistula access has been considered optimum for hemodi-
alysis management [16], there is little outcome data con-
cerning vascular access in children available at the pres-
ent time. From the 2001 United States Renal Data
System (USRDS) Annual Report data, over one half of
the children starting dialysis are transplanted within the
2 years [17]. Moreover, the surgical creation of a fistula
in smaller children can be challenging technically. Given
the turnover rate, potential surgical difficulties, and ade-
quacy data that appear to exceed K/DOQI guidelines,
catheter placement may be an appropriate choice for
some children at least initially. Whether the higher clear-
ances achieved by using a fistula access would really
affect anemia and other ESRD-related morbidity in chil-
dren maintained on chronic hemodialysis has yet to be
shown.
Almost all the patients had iron supplements pre-
scribed. Dosage of both intravenous and oral iron and
the compliance of the oral agents were not monitored
in this study. Despite the prescription for iron, there was
evidence for persistent iron deficiency (low TSAT and
serum ferritin) in many children. Insufficient iron admin-
istration clearly may have been a factor contributing to
the muted response to the erythropoietin seen in some
patients. Moreover, no information concerning the pres-
ence of comorbid conditions such as inflammatory pro-
cesses and/or hyperparathyroidism was available. Such
data may also be important in assessing the degree of
anemia since the presence of chronic inflammation and
severe hyperparathyroidism could adversely influence
the response to erythropoietin.
Insufficient dialysis is associated with significant clini-
cal morbidity, an increased risk of mortality [18], and
likely contributes to anemia [18, 19]. However, results
from the National Institutes of Health (NIH) sponsored
Hemodialysis (HEMO) Trial demonstrate that markedly
exceeding current dialysis clearance above current guide-
lines may not reduce preexisting morbidity or lower mor-
tality rates [20]. From the present study, it appears as
though exceeding the guidelines for dialysis adequacy
does not affect the degree of anemia. Alternative expla-
nations need to be considered to account for the anemia.
Low serum albumin and anemia were related in adult
patients maintained on hemodialysis but in the context
of inadequate dialysis clearance [18]. Our observations
raise the possibility that these two variables, anemia and
albumin, are associated independent of clearance and
support the view that poor nutrition may be an additional
factor. Relative iron deficiency in our population could
also be a manifestation of poor nutrition. This hypothesis
needs to be studied further using additional and perhaps
more specific surrogate markers for nutrition than al-
bumin.
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